Universitätsklinikum Tübingen


Location: Tübingen, Germany (DE) DE

ISNI: 0000000101968249

ROR: https://ror.org/00pjgxh97

Show on Map:


Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year




PATHFINDER-CHD: prospective registry on adults with congenital heart disease, abnormal ventricular function, and/or heart failure as a foundation for establishing rehabilitative, prehabilitative, preventive, and health-promoting measures: rationale, aims, design and methods (2024) Freilinger S, Kaemmerer H, Pittrow RD, Achenbach S, Baldus S, Dewald O, Ewert P, et al. Journal article Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer (2024) Fasching P, Hu C, Hart SN, Rübner M, Polley EC, Gnanaolivu RD, Hartkopf AD, et al. Journal article Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article Quality of life of short-statured children and adolescents and growth hormone treatment Lebensqualität von kleinwüchsigen Kindern und Jugendlichen und Wachstumshormontherapie (2024) Quitmann JH, Binder G, Witt S, Bullinger M, Blömeke J, Fricke-Otto S, Hauffa B, et al. Journal article Variable Clinical Courses of Varicella Zoster Virus Infection–related or Vaccination-related Bone Marrow Failure (2024) Toskov V, Cseh A, Claviez A, Drexler B, Rotari N, Schwarz-Furlan S, Braun M, et al. Journal article Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry Real-World-Daten des deutschen PRAEGNANT-Registers zu Therapieabbr chen der ersten 3 Therapielinien bei Patientinnen mit fortgeschrittenem Brustkrebs (2024) Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching P, Ettl J, et al. Journal article CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - An Overview of Current Programs CDK4/6-Inhibition: Sequenztherapien und die Suche nach den besten Biomarkern ein berblick ber die aktuellen Programme (2024) Schneeweiss A, Brucker SY, Hübner H, Volmer LL, Hack C, Seitz K, Rübner M, et al. Journal article, Review article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Rescue Allocation Modes in Eurotransplant Kidney Transplantation: Recipient Oriented Extended Allocation Versus Competitive Rescue Allocation - A Retrospective Multicenter Outcome Analysis (2024) Assfalg V, Miller G, Stocker F, Hüser N, Hartmann D, Heemann U, Tieken I, et al. Journal article How do mindfulness-based interventions promote coping and self-efficacy in patients with cancer: A systematic review of qualitative and quantitative data (2024) Heinen JM, Laing EM, Schäffeler N, Bäuerle A, Krakowczyk JB, Schug C, Ziesemer SK, et al. Journal article, Review article